hCG vs Enclomiphene: What to Choose and for Whom
When hCG and enclomiphene are compared, the question of ‘which is better’ is almost always posed incorrectly. The right question is: for whom, with what diagnosis, and for what purpose. The editorial team analyzed the typical clinical scenarios in which doctors choose between these approaches, as well as the situations in which neither of them is the answer.
Where the choice begins: the diagnosis
Low testosterone is a symptom, not a diagnosis. It can be the consequence of damage to the testicles themselves (primary hypogonadism), a disruption of the pituitary or hypothalamus (secondary hypogonadism), obesity, chronic stress, the use of certain medications, or prolonged use of anabolic steroids. Whether hCG or enclomiphene make sense at all depends on the level at which the problem arose.
The clinical guidelines of the Endocrine Society (2018) require confirming testosterone deficiency with at least two morning fasting tests and combining laboratory indicators with the presence of symptoms. A single low result after a sleepless night or an illness is not grounds for treatment.
The next step is measuring LH and FSH. High gonadotropins against a background of low testosterone point to a primary problem in the testicles. Low or ‘normal’ gonadotropins with low testosterone indicate a secondary nature of the disorder. It is precisely this fork that is most important for choosing between hCG, estrogen receptor modulators and replacement therapy.
In addition, the doctor assesses prolactin, estradiol, thyroid-stimulating hormone, ferritin, and in secondary hypogonadism of unclear cause may order an MRI of the pituitary. For men planning children, a semen analysis is mandatory.
- Total testosterone (twice, in the morning) and, if needed, free testosterone or SHBG.
- LH, FSH, estradiol, prolactin.
- Semen analysis — if fertility matters.
- Complete blood count, lipid profile, glucose — as a basic health assessment.
When doctors lean toward hCG
hCG is the drug of choice in situations where the pituitary is unable to produce enough LH. The classic example is congenital hypogonadotropic hypogonadism (in particular Kallmann syndrome) or acquired pituitary damage after a tumor, surgery or radiation. Here stimulating the brain with enclomiphene is pointless, because the ‘lower’ link will not respond, whereas hCG directly replaces the missing signal.
The second group is men with secondary hypogonadism who want to have children. If necessary, doctors combine hCG with FSH preparations, since full spermatogenesis requires both signals. Such regimens last for months and are carried out in specialized reproductive medicine centers.
The third situation is men on testosterone replacement therapy for whom preserving fertility is important. A retrospective study by Hsieh et al. (2013) showed that concurrent administration of hCG helped preserve spermatogenesis in most patients on replacement therapy. This is not a standard for everyone but an individual decision by the andrologist.
Finally, hCG is used in pediatrics to treat cryptorchidism and, in certain cases, delayed puberty. These indications lie entirely within the field of pediatric endocrinology and urology.
When enclomiphene or a SERM is considered
Estrogen receptor modulators make sense when the hypothalamus–pituitary–testicular axis is structurally intact but works insufficiently actively. A typical example is functional secondary hypogonadism in obese men, in whom an excess of estrogens formed in adipose tissue suppresses the gonadotropins. It was precisely this population that Kim et al. (2016) studied in trials of enclomiphene.
The main advantage of this approach is oral intake and preservation of the body's own spermatogenesis. For a young man planning children, testosterone replacement therapy is undesirable because it suppresses spermatogenesis, and this is exactly why a SERM is considered an alternative. However, enclomiphene is not registered in most countries, so in practice doctors more often use clomiphene off-label.
A systematic review and meta-analysis by Huijben et al. (2022) on clomiphene in men with hypogonadism confirmed that the drug raises testosterone levels, but the quality of evidence regarding its effect on symptoms and long-term safety was assessed as limited. This is an important caveat: a rise in a laboratory indicator does not yet mean an improvement in well-being.
SERMs are also considered after discontinuing anabolic steroids, when the body's own axis is suppressed. A review by Rahnema et al. (2014) describes such approaches as part of the medical management of steroid-induced hypogonadism, emphasizing that the decision and monitoring must be in the hands of a doctor, and that recovery is not guaranteed.
For whom neither option is suitable
In primary hypogonadism, when the testicles themselves are damaged (for example, Klinefelter syndrome, the aftermath of trauma, chemotherapy or orchitis), neither hCG nor enclomiphene will produce a significant effect: the pituitary is already working at maximum, and the testicles are unable to respond. In such patients, if treatment is needed, doctors discuss testosterone replacement therapy.
Nor should either agent be considered without a confirmed diagnosis — merely out of a ‘wish to have more energy’ or for preventive purposes. The Endocrine Society guidelines explicitly do not recommend hormonal therapy for men without an established deficiency.
Contraindications to hCG include hormone-dependent tumors (in particular prostate and breast cancer in men), pituitary tumors, and precocious puberty. For SERMs, a history of thrombosis, liver disease and vision problems are significant.
| Situation | hCG | Enclomiphene / SERM |
|---|---|---|
| Congenital hypogonadotropic hypogonadism | Considered | Usually ineffective |
| Functional secondary hypogonadism, obesity | Possible | Considered |
| Primary hypogonadism | Ineffective | Ineffective |
| Preserving fertility on replacement therapy | Considered | Sometimes as an alternative to replacement therapy |
| History of thrombosis | Physician's judgment | Undesirable |
| Professional sport | Banned by WADA | Banned by WADA |
A separate word should be said about women. In women, hCG is used in reproductive medicine under a strict protocol, and enclomiphene as a standalone agent is not used in women; for ovulation induction, clomiphene and letrozole are known. Any use of these agents by women for the purpose of changing physique is dangerous and has no medical justification.
Sport, doping control and self-medication
For athletes who fall under anti-doping rules, the question of choice does not arise at all. hCG and LH are prohibited for men in section S2 of the WADA Prohibited List, and clomiphene and other antiestrogenic agents in section S4. The ban applies at all times, and a reference to ‘hormone recovery’ does not exempt one from responsibility without an approved therapeutic use exemption.
Outside professional sport, the practice of self-administering these substances after steroid courses is widespread. The editorial team emphasizes: without tests it is impossible to understand whether the axis is recovering or is being suppressed even more, and side effects (estrogenic manifestations from hCG, visual disturbances from clomiphene) may go unnoticed until serious symptoms appear.
Another problem is counterfeits. Unregistered enclomiphene is sold as ‘research chemistry’ without any composition guarantees, and hCG of unofficial origin often does not contain the stated activity. A person wastes time while the hormonal system remains suppressed.
If symptoms of hypogonadism appear after using anabolic steroids — fatigue, depressed mood, decreased libido — the safest step is to consult an endocrinologist or andrologist and honestly describe the prior experience. The doctor will be able to assess the situation and propose an evidence-based plan.
Editorial conclusions
hCG is more appropriate where the pituitary is unable to produce LH, as well as in reproductive scenarios that require direct stimulation of the testicles. Estrogen receptor modulators, in particular enclomiphene, are considered when the axis is intact but ‘slowed down’, and when it is important to preserve one's own spermatogenesis without injections.
In primary hypogonadism neither of these approaches works, and for athletes both are banned. The regulatory status of enclomiphene also limits its real use in medicine.
The main rule of choice is: first the diagnosis, then the drug. Without measuring LH, FSH and the cause of the disorder, any decision is a lottery with one's own health.
For a deeper understanding of the topic we recommend our materials on the mechanistic differences between hCG and enclomiphene, on the comparison of tamoxifen and enclomiphene, and on restoring the hormonal axis after anabolic steroids.
References
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744.
- Hsieh TC, Pastuszak AW, Hwang K, Lipshultz LI. Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. J Urol. 2013;189(2):647–650.
- Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117(4):677–685.
- Huijben M, Lock MTWT, de Kemp VF, et al. Clomiphene citrate for men with hypogonadism: a systematic review and meta-analysis. Andrology. 2022;10(3):451–469.
- Rahnema CD, Lipshultz LI, Crosnoe LE, et al. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101(5):1271–1279.
- Wiehle RD, Fontenot GK, Wike J, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertil Steril. 2014;102(3):720–727.
- World Anti-Doping Agency. Prohibited List. Montreal: WADA (чинна редакція).
Andriy Melnyk
A strength-sports coach and author of programs for beginner and intermediate levels. Writes about training planning.
